Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HJB647 in Japanese Healthy Participants With Elevated Blood Pressure and Patients With Hypertension
NCT07644364Phase 1Recruiting
- Sponsor
- Novartis
- Start
- Jul 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HJB647 in hypertension (HTN) (10 arms), sponsored by Novartis. Primary endpoints: Maximum Observed Plasma Concentration at Day 1, Time to Maximum Observed Plasma Concentration at Day 1 and 4 more. Started Jul 2026; status: recruiting.
02
Drugs
HJB647
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT07644364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07644364.